BioSpace News Archive

INVO Bioscience, Inc., a medical device company focused on commercializing the world’s only in vivo culture system, announced it will regain full U.S. commercialization rights for its patented INVOcell® device due to Ferring International Center S.A.'s termination for convenience of that certain Distribution Agreement dated November 12, 2018 with INVO, which termination will officially take effect on January 31, 2022.

Titan Pharmaceuticals, Inc. announced that, in a presentation given at the Society for Neuroscience 2021 Meeting, Ben Land, Ph.D., Research Assistant Professor at the University of Washington’s Department of Pharmacology, reported additional positive data from an ongoing in vivo study of its human kappa-opioid receptor agonist ProNeura®-based implant in an established 5'-guanidinonaltrindole itch-induced mouse model.

Guardant Health, Inc., a leading precision oncology company, announced the company will be participating virtually in the upcoming 2021 Stifel Healthcare Conference.

Castle Biosciences, Inc., a company applying innovative diagnostics to inform disease management and improve patient outcomes, announced its financial results for the third quarter and nine months ended Sept. 30, 2021.

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced financial results for its third quarter ended September 30, 2021.

AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, reported financial results for the third quarter ended September 30, 2021 and provided a business update.

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (ANI or the Company) today announced the closing of its previously announced underwritten public offering.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that management will participate in three upcoming investor conferences.

ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, announced that Company management will participate in the following upcoming investor conferences

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced that Loïc Moreau will join Nyxoah as CFO as of January 1, 2022.